Drug Trial Radar · NCT00430092
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Sirion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
Summary
As written by the sponsor on the registry.
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
Conditions
- Inflammation
Interventions
DifluprednateDrug
DifluprednateDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).Time frame: Day 8 (QID)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Comprehensive Eye Care
Washington, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.